CALABRETTA, Bruno
 Distribuzione geografica
Continente #
NA - Nord America 20.908
EU - Europa 7.730
AS - Asia 3.520
SA - Sud America 183
Continente sconosciuto - Info sul continente non disponibili 29
AF - Africa 21
OC - Oceania 9
Totale 32.400
Nazione #
US - Stati Uniti d'America 20.863
GB - Regno Unito 3.478
SE - Svezia 1.032
SG - Singapore 1.023
CN - Cina 1.003
HK - Hong Kong 884
UA - Ucraina 658
IT - Italia 649
DE - Germania 620
TR - Turchia 401
RU - Federazione Russa 398
FI - Finlandia 357
BG - Bulgaria 259
BR - Brasile 165
FR - Francia 107
ID - Indonesia 78
CA - Canada 36
IE - Irlanda 36
BE - Belgio 34
IN - India 33
NL - Olanda 33
EU - Europa 25
CZ - Repubblica Ceca 16
IR - Iran 16
AT - Austria 12
MY - Malesia 12
VN - Vietnam 11
JP - Giappone 10
LT - Lituania 10
BD - Bangladesh 8
MA - Marocco 8
AU - Australia 6
CH - Svizzera 6
PL - Polonia 6
UZ - Uzbekistan 6
AR - Argentina 5
A2 - ???statistics.table.value.countryCode.A2??? 4
ES - Italia 4
GR - Grecia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BZ - Belize 3
DZ - Algeria 3
EC - Ecuador 3
KE - Kenya 3
KR - Corea 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
PE - Perù 3
PK - Pakistan 3
AZ - Azerbaigian 2
CO - Colombia 2
DO - Repubblica Dominicana 2
EG - Egitto 2
HR - Croazia 2
IL - Israele 2
IQ - Iraq 2
JO - Giordania 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MX - Messico 2
OM - Oman 2
SI - Slovenia 2
ZA - Sudafrica 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
GE - Georgia 1
GH - Ghana 1
HU - Ungheria 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 32.400
Città #
Southend 3.067
Fairfield 2.810
Woodbridge 2.275
Santa Clara 1.838
Houston 1.607
Jacksonville 1.534
Ashburn 1.207
Ann Arbor 1.133
Chandler 1.095
Cambridge 1.000
Seattle 997
Wilmington 996
Dearborn 902
Hong Kong 880
Nyköping 746
Singapore 696
Modena 422
San Diego 331
Beijing 295
Princeton 270
Sofia 258
Eugene 250
Izmir 210
Des Moines 122
Helsinki 120
Moscow 108
New York 105
Redwood City 102
London 95
Falls Church 82
Jakarta 78
Shanghai 67
Boardman 53
Norwalk 52
Nanjing 37
Dublin 36
Brussels 34
Hefei 34
Milan 29
Bremen 27
Hounslow 26
Toronto 25
Guangzhou 24
Kilburn 24
Dongguan 21
Fremont 21
Kunming 20
Philadelphia 20
Saint Petersburg 20
Nuremberg 19
Chicago 17
Chiswick 16
Verona 16
Brno 14
Indiana 14
San Mateo 14
Mountain View 12
Frankfurt am Main 11
Grafing 11
Phoenix 11
Prescot 11
Jinan 10
San Jose 10
Zhengzhou 10
Monmouth Junction 9
Munich 9
North Bergen 9
Ottawa 9
Rome 9
São Paulo 9
Ardabil 8
Auburn Hills 8
Dong Ket 8
Dronten 8
Los Angeles 8
Shenyang 8
Washington 8
Dallas 7
Fuzhou 7
Groningen 7
Nanchang 7
Parma 7
Vienna 7
Augusta 6
Campinas 6
Islington 6
Wuhan 6
Amsterdam 5
Chongqing 5
Hanover 5
San Francisco 5
Athens 4
Changsha 4
Chengdu 4
Hangzhou 4
Kraków 4
Lausanne 4
Leawood 4
Occhiobello 4
Pune 4
Totale 26.629
Nome #
KLF4 mediates the effect of 5-ASA on the b-catenin pathway in colon cancer cells 326
Expression of μ-protocadherin is negatively regulated by the activation of the β-catenin signaling pathway in normal and cancer colorectal enterocytes 261
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells 260
Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules identified through interrogation of the Connectivity Map database 259
Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility 256
Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants 235
Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity 230
Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis 220
BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. 213
c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells 213
Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells. 206
Phosphorylation of serine 21 modulates the proliferation inhibitory more than the differentiation inducing effects of C/EBPα in K562 cells. 199
A degradation-resistant c-Myb mutant cooperates with Bcl-2 in enhancing proliferative potential and survival of hematopoietic cells 197
CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia 192
hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis 192
BCR-ABL prevents c-Jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase C beta II-dependent pathway 191
The p53 Codon 72 Pro/Pro Genotype Identifies Poor-Prognosis Neuroblastoma Patients: Correlation with Reduced Apoptosis and Enhanced Senescence by the p53-72P Isoform. 190
Altered expression of G1 specific genes in human malignant myeloid cells. 189
Regulation of Balb/c3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. 188
Effects of C/EBP alpha and C/EBP beta in BCR/ABL-expressing cells - Differences and similarities 186
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients 183
Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells viatranscriptional repression of STAT 5 and Mcl-1 183
Inhibiting interactions of lysine demethylase LSD1 with Snail/Slug blocks cancer cell invasion. 183
Activation of human B-MYB by cyclins. 181
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients 180
Cell-cycle-dependent expression of human ornithine decarboxylase. 179
Positive autoregulation of c-myb expression via myb binding sites in the 5' flanking region of the human c-myb gene 175
Suppression of autophagy by BCR/ABL 175
Different frequency classes of sequences in heterogeneous nuclear RNA of normal promyelocytes and lymphoblasts and of leukemic blast cells of circulating blood and of the HL60 line. 175
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. 174
TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis 174
Expression of Slug Is Regulated by c-Myb and Is Required for Invasion and Bone Marrow Homing of Cancer Cells of Different Origin 174
Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors 174
Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia 174
Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects 173
Regulation of microRNA-145 by growth arrest and differentiation. 172
Coding sequence and growth regulation of the human vimentin gene. 172
Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk 170
Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. 169
Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide 166
Structure of Nascent Chromatin Is Essential for Hematopoietic Lineage Specification 166
The transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation 165
Antisense oligonucleotides. 165
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. 165
Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of bcl-2 expression and Myb-dependent regulation of bcl-2 promoter activity 164
The transcription factors c-myb and GATA-2 act independently in the regulation of normal hematopoiesis. 164
BCR/ABL activates mdm2 rnRNA translation via the La antigen 163
Antileukemia effect of c-myc N3′→P5′ phosphoramidate antisense oligonucleotides in vivo 163
Guidelines for the use and interpretation of assays for monitoring autophagy. 163
Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants. 162
Oligonucleotide N3'-->P5' phosphoramidates as antisense agents. 162
Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BICRABL-expressing cells 160
Role of pescadillo and upstream binding factor in the proliferation and differentiation of murine myeloid cells 160
Antisense myb inhibition of purified erythroid progenitors in development and differentiation is linked to cycling activity and expression of DNA polymerase alpha. 160
Altered mRNA translation: possible mechanism for CML disease progression. 159
The Jun family members, c-Jun and JunD, transactivate the human c-myb promoter via an Ap1-like element. 159
Leukemia stem cells: Old concepts and new perspectives 159
Versatility of BCR/ABL-expressing leukemic cells in circumventing pro-apoptotic BAD effects 158
Ectopic expression of A-myb in transgenic mice causes follicular hyperplasia and enhanced B lymphocyte proliferation. 158
A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. 157
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant 157
Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells 156
Translational regulation by the p210 BCR/ABL oncoprotein 155
miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. 155
Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. 155
B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. 154
Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. 154
Tumorigenic conversion of p53 deficient colon epithelial cells by an activated Ki-ras gene 154
Expression of CCL9/MIP-1γ is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells 153
Physical interaction between CDK9 and B-MYB results in suppression of B-MYB gene autoregulation. 151
Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells 151
B-myb alters the response to myeloid precurson cells to G-CSF 149
G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. 148
A cell proliferation-dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing element. 148
Presence of a highly repetitive and widely dispersed DNA sequence in the human genome. 148
Cyclin D1-dependent regulation of B-myb activity in early stages of neuroblastoma differentiation. 148
Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. 147
Transformation of hematopoietic cells by BCR/ABL requires activation of PI-3k/Akt dependent pathway. 147
Role of the c-myb and c-abl protooncogenes in human hematopoiesis. 146
TGF-β-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells. 145
Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. 145
Role of p53 in hematopoietic recovery after cytotoxic treatment. 145
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. 144
Expression of c-myc and induction of DNA synthesis by platelet-poor plasma in human diploid fibroblasts. 144
Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. 143
Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. 143
Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. 141
An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. 141
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. 141
Direct transactivation of the anti-apoptotic gene Apolipoprotein J (Clusterin) by B-MYB. 140
The RB-related gene Rb2/p130 in neuroblastoma differentiation and in B-myb promoter down-regulation. 140
Prospects for gene-directed therapy with antisense oligodeoxynucleotides. 140
Characteristics of macromolecular RNA metabolism in leukemic promyelocytes of the HL 60 line 140
Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models 139
Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. 139
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2 139
Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise? 139
HLA DR associated invariant chain is highly expressed in chronic lymphocytic leukemia. 138
Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. 138
Functional significance of c-myb expression in normal and leukemic hematopoiesis. 138
Totale 16.979
Categoria #
all - tutte 140.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.582


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.850 0 0 0 0 0 0 0 527 567 172 362 222
2020/20214.668 482 150 375 366 634 245 540 640 161 615 275 185
2021/20224.087 85 611 409 248 127 197 274 218 439 272 738 469
2022/20233.287 442 373 245 304 355 528 79 318 416 36 112 79
2023/20241.946 82 126 134 158 502 183 274 187 43 19 53 185
2024/20254.259 210 29 56 482 1.454 1.048 754 226 0 0 0 0
Totale 32.480